LGVN - Longeveron Reports Positive Top-Line Phase 2a Clinical Trial Results for Lomecel-B

2023-10-05 09:35:24 ET

DENVER, Colo., Oct 5, 2023 ( www.247marketnews.com)- Longeveron Inc. (NASDAQ: LGVN) reported, this morning, positive top-line results from its Lomecel-B, its investigational product, Phase 2a trial for the treatment of mild Alzheimer’s disease. The Company is hosting a conference call and webcast today at 8:00 AM ET to discuss the results, which includes primary safety endpoint met across all study groups, with additional biomarker data expected to be announced in the coming weeks

Longeveron is trading at $2.64, up $0.13 (+5.18%), on 5.95M premarket shares traded.

Its 52-week range is $2.12 to $4.5793. It bounced off of its 52-week low, a few weeks ago, and hit a high of $3.85, two minutes after the announcement. Its next key resistance is …

The post Longeveron Reports Positive Top-Line Phase 2a Clinical Trial Results for Lomecel-B appeared first on 24/7 Market News .

For further details see: